A1LN34.SA Alnylam Pharmaceuticals, Inc.

Healthcare Biotechnology Sao Paulo Exchange
44.50 BRL
Close of Nov 5, 2026
43.32 126.48
Market cap
BRL 119B
P/E
8.7x
P/B
6.03x
ROE
93.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is A1LN34.SA undervalued?

Graham number
Price44.50
Graham value29.17
Premium52.6%

A1LN34.SA trades 52.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Alnylam Pharmaceuticals, Inc. fundamental analysis

No fundamental analysis for Alnylam Pharmaceuticals, Inc. yet.

Alnylam Pharmaceuticals, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops …

Full company profile